A Multicenter, Phase 1/2, Open-Label Study Evaluating the Tolerability, Safety, Pharmacokinetics, and Efficacy of AMG 337 in Asian Subjects
Phase of Trial: Phase I/II
Latest Information Update: 27 Dec 2018
Price : $35 *
At a glance
- Drugs AMG 337 (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Amgen
- 10 Sep 2018 Planned End Date (this date is the expected follow-up date for patients receiving therapy after trial termination) changed from 30 Sep 2018 to 7 Dec 2018.
- 31 Aug 2018 Biomarkers information updated
- 17 Nov 2017 Planned End Date changed from 29 Dec 2017 to 29 Jun 2018.